Hosted on MSN10mon
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
In the announcement accompanying the trial results, Stephanie Fradette, head of the neuromuscular development unit at Biogen said: “While BIIB105 lowered ATXN2 protein, it did not reduce ...
MarketWatch1mon
Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...
pharmaphorum2d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results ... is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. It is thought that CD38-expressing ...